GLI3抗体;GLI3 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P13144(GLI3 Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P13144(GLI3 Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

The GLI3 antibody is a crucial tool for studying the GLI family zinc finger transcription factor 3 (GLI3), a key mediator of the Hedgehog (Hh) signaling pathway. GLI3 regulates embryonic development, particularly in limb formation, neural tube patterning, and organogenesis. It functions as both a transcriptional activator and repressor, with its activity finely tuned by Hh signaling gradients. In the absence of Hh ligands, GLI3 undergoes proteolytic processing into a repressor form, while Hh activation promotes its full-length activator state. Dysregulation of GLI3 is linked to developmental disorders such as Greig cephalopolysyndactyly syndrome, Pallister-Hall syndrome, and certain cancers.

GLI3 antibodies are widely used in research to detect protein expression, localization, and post-translational modifications via techniques like Western blotting, immunohistochemistry, and immunofluorescence. They help elucidate GLI3's role in Hh pathway dynamics, ciliary function, and tissue-specific regulatory mechanisms. Commercially available antibodies often target conserved epitopes, such as the N-terminal repressor domain or C-terminal activator regions. Validation includes testing in GLI3-knockout models or siRNA-treated cells to ensure specificity. Researchers also employ these antibodies to study GLI3 interactions with other pathway components (e.g., SUFU, PTCH1) and its crosstalk with Wnt or FGF signaling. Ongoing studies focus on GLI3's implications in regenerative medicine and targeted cancer therapies, particularly in tumors with aberrant Hh pathway activation.